C

Cooper Companies

Global medical devices and vision care

Senior Business Analyst

Full-TimePosted on 10/22/2026
$100k - $110k
Mid, Senior
Bachelor's
Trumbull, CT, USA+1 moreMore locations: Livingston, NJ, USA
In PersonOn-site in Trumbull, CT or Livingston, NJ; up to 10% domestic travel may be required.
Data & AnalyticsBusiness Intelligence

About the job

Requirements
  • Three to five years of experience in business intelligence, analytics, business analysis, or related roles.
  • Experience or strong knowledge in supply chain, including inventory, planning, manufacturing or operations, logistics, or service levels.
  • Experience building operational Excel-based tools, reconciliations, trackers, or semi-automated reporting solutions for business users.
  • A Bachelor's degree in IT, Industrial Engineering, Business Administration, Data/Analytics, Programming, Engineering, Computer Science, or a similar field, or equivalent experience.
  • Advanced Excel skills, including complex formulas, Power Query, pivot tables, data validation, reconciliation, scenario analysis, and creating maintainable operational tools; VBA/macros are a plus.
  • Intermediate proficiency in Power BI and DAX, with experience in report design, data modeling, visualization, and performance optimization.
  • SAP BusinessObjects experience is a strong asset.
  • Experience using ERP platforms such as Microsoft Dynamics 365 or comparable systems is beneficial.
  • Working proficiency with SQL is strongly preferred; familiarity with Python/VBA is a plus.
  • Ability to learn complex processes, understand key data flows, and identify improvement opportunities.
  • Experience using ERP or other operational systems for data validation, transaction-level reconciliation, and root-cause investigation between source systems and reporting outputs.
  • Ability to manage multiple concurrent initiatives, balance competing priorities, and communicate status, risks, and tradeoffs.
  • Ability to collaborate cross-functionally, including with Data Engineering and IT, to define data needs and troubleshoot reporting or data issues.
  • Ability to distill complex data into clear, concise insights for technical and non-technical audiences.
  • High attention to detail and data quality, with a consistent track record of meeting commitments.
  • Effective verbal and written communication in English is required.
  • Successful completion of an applicable employment and education background check.
Responsibilities
  • Own assigned business problems and independently drive them to resolution using data, process knowledge, and stakeholder collaboration.
  • Build pragmatic, usable solutions quickly, with clear assumptions and a path toward scalable improvement.
  • Challenge over-engineered solutions and prioritize simplicity, usability, and business impact.
  • Translate supply chain process needs into data models, analyses, reports, KPIs, and decision tools.
  • Act as a bridge between business and technical teams to ensure solutions are usable and sustainable.
  • Collaborate primarily with Global Supply Chain stakeholders to define business requirements and translate them into actionable analytics and reporting plans.
  • Build and improve dashboards and KPI frameworks supporting operational efficiency, inventory visibility, demand planning, and service levels.
  • Lead reporting initiatives through intake, discovery, requirements, build, QA/UAT, release, training, adoption, and iterative enhancement.
  • Implement improvements that reduce manual effort, improve reliability, and increase stakeholder self-service capability.
  • Coordinate with Data Engineering and IT on source-system integration, dataset design, refresh reliability, and data quality controls; validate end-to-end lineage from source to dashboard.
  • Support intake, prioritize enhancements and ad hoc requests, and identify repeatable solutions for frequent asks.
  • Maintain stakeholder alignment by communicating scope, timelines, dependencies, and release cadence; communicate status and risks proactively.
  • Use Excel, SQL, or Power BI according to the speed, complexity, and long-term needs of the problem.
  • Build interim/manual solutions, including Excel models, Power Query transformations, quick extracts, reconciliations, and SQL queries, while designing future-state automation.
  • Investigate process and data issues and work with business and technical partners to identify root causes.
  • Simplify complex problems into clear, actionable outputs for business stakeholders.
  • Drive the transition from manual to semi-automated to fully automated solutions.
  • Develop, enhance, and maintain BI solutions and reporting using Power BI (including DAX), SAP BusinessObjects, and Excel/VBA.
  • Design and maintain Power BI semantic models and datasets, improving usability, performance, and refresh reliability.
  • Conduct data validation, reconciliation, and quality assurance to ensure accurate and trusted reporting outputs.
  • Reconcile KPIs and metrics against ERP and other source systems, investigate variances, and document findings.
  • Analyze data to uncover trends, risks, and opportunities, translating insights into practical recommendations.
  • Lead requirements-gathering workshops and document functional specifications and acceptance criteria.
  • Provide break-fix reporting support, including issue triage, root-cause analysis, and resolution documentation; escalate complex issues when appropriate.
  • Manage assigned reporting initiatives and enhancements simultaneously, including intake, prioritization, scope, timelines, risks, dependencies, and stakeholder communications; maintain a structured backlog of enhancements and new requests.
  • Collaborate with Data Engineering and IT to define data requirements, improve pipeline reliability, resolve data issues, and ensure governed datasets support reporting needs end-to-end.
  • Provide timely ad hoc analysis and reporting support, document logic and assumptions, and standardize recurring requests where appropriate.
  • Collaborate within the Global Supply Chain Analytics & Data Science team to standardize KPI definitions, improve data literacy, and increase adoption of self-service reporting.
  • Support continuous improvement initiatives with business leaders and process owners.
  • Perform additional duties as assigned.
  • Serve as a technical mentor, coaching Business Analysts on data modeling, DAX best practices, visualization standards, quality assurance, documentation, and report lifecycle management.
  • Share knowledge with peers and continue building capability in data modeling, DAX, visualization, and reporting lifecycle management.
  • Travel up to 10% domestically to support cross-functional collaboration, operational reviews, or analytics workshops.
Desired Qualifications
  • Microsoft Power BI Data Analyst certification or equivalent training.
  • Microsoft Excel certification or advanced Excel training.
  • Data visualization training.
  • PMP or agile project management training.

About the company

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

San Ramon, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 23, 2026 Vision Centre launch accelerates six contact-lens products over several years.
  • Q3 fiscal 2026 free cash flow hit $273 million, up 66% year over year.
  • MiSight grew 20% organically, while MyDay posted double-digit growth in Q3 2026.

What critics are saying

  • Q3 2026 revenue missed by $30 million, and CooperVision destocking continues into Q4.
  • Accrued litigation liability jumped to $316.5 million on July 31, 2026.
  • Kirby McInerney opened a securities investigation after the September 9, 2026 earnings drop.

What makes Cooper Companies unique

  • CooperVision's Southampton Vision Centre unites R&D, pilot manufacturing, clinics, and commercialization.
  • CooperVision reaches 40 million people worldwide through contact lenses and myopia-control leadership.
  • CooperSurgical combines fertility, genomics, and women's-health devices under one vertically integrated platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Performance Bonus
  • Health Insurance
  • 401(k) Retirement Plan
  • Life Insurance
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Sep 24th, 2026
CooperVision opens global innovation hub in Southampton, unveils six new contact lens products

The Cooper Companies has opened The Vision Centre, a global innovation hub in Southampton, England, to accelerate contact lens development for its CooperVision business. The facility integrates research and development, clinical expertise, pilot manufacturing and commercial capabilities under one roof. CooperVision announced six product advancements across myopia control, silicone hydrogel, toric and multifocal contact lenses, with launches planned over coming years. The pipeline includes a complete family of one-day contact lenses for myopia control and a premium one-day silicone hydrogel technology. Following the announcement, COO stock gained 1.4%. Year to date, shares have declined 31.6% against the industry's 2.8% growth. The company has a market capitalisation of $10.51 billion. CooperVision's products currently reach more than 40 million people worldwide.

Associated Press
Sep 24th, 2026
Cooper Companies shares drop 14.7% after missing Q3 revenue target by $30M

Cooper Companies' shares fell 14.7% on 10 September 2026 after the medical device company reported third-quarter revenue of $1.07 billion, missing analyst expectations of $1.10 billion by $30 million. The company attributed the shortfall to its CooperVision segment, which generated $717 million in quarterly revenue, flat year-over-year. Cooper Companies said it had "proactively reduced U.S. channel inventory" in CooperVision, which would continue to impact fourth-quarter results. The share price dropped from $63.48 to close at $54.17 following the announcement. Law firm Kirby McInerney has announced an investigation into possible securities law violations by the company and its senior management. No lawsuit has been filed yet.

PR Newswire
Sep 14th, 2026
The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS.

The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS. Sep 14, 2026, 12:46 ET SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ - investors in The Cooper Companies, Inc. (NASDAQ: COO) saw the price of their shares trade down $9.31 (-14.6%) after the company reported Q3 2026 financial results that included revelations of its U.S. channel inventory destocking along with other negative surprises. The stock's move lower wiped out over $1.7 billion of the company's market capitalization. The revelations have prompted national shareholders rights firm Hagens Berman to open an investigation into whether The Cooper Companies was sufficiently transparent beforehand about its sales practices and, if not, whether it may have violated the securities laws. The firm encourages Cooper investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys. The Cooper Companies (COO) Investigation Cooper is a global medical device company with two reporting segments. The largest - CooperVision - manufactures and markets hydrogel lens products for contact lens wearers and accounted for roughly 67% of Cooper's total consolidated sales in fiscal 2025. The investigation is focused on the propriety of Cooper's statements about the mechanics contributing to CooperVision's revenue growth and its sustainability. During Cooper's June 4, 2026 Q2 2026 earnings call, management emphasized CooperVision's "solid quarter, with revenues increasing 8%, or 4% organically" and guided for CooperVision full year organic revenue growth of 3.5% to 4.5%, emphasizing that "[f]or CooperVision [...] [o]utside of Asia Pac, demand remains solid for premium products, including daily silicone hydrogel lenses as well as torics and multifocals." The next day, the price of Cooper shares traded almost 8% higher. Investors received some troubling news on September 9, 2026, when the company reported its Q3 2026 financial results. In particular, Cooper's management revealed "our legacy hydrogels were down double-digit across the board[,]" "the results in the Americas reflected CooperVision's US channel inventory reductions[,]" and "[w]e expect CooperVision revenue of $692 million to $706 million down 2% to flat organically." In response to an analyst's question during the earnings call about whether the entirety of the reduced guide for CooperVision revenue was inventory-related, CEO Albert White III said, "it's all destock [...] [m]eaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory." Another analyst expressed concern, asking "why are they destocking [...] [d]id you guys have too much inventory in the channel from past efforts to kind of prop up numbers?" The market did not take kindly to the developments and sent the price of Coopers shares down over 14% the next day to close at a 52-week low of $54.17, with several analysts reportedly downgrading their ratings and price targets. "We're focused on whether Cooper was sufficiently transparent to investors about its CooperVision sales strategies," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in Cooper and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now" Whistleblowers: Persons with non-public information regarding Cooper should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. SOURCE Hagens Berman Sobol Shapiro LLP

Yahoo Finance
Sep 14th, 2026
Cooper Companies cuts 2026 forecast as contact lens demand weakens, CooperVision revenue drops to $717M

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.

Yahoo Finance
Sep 10th, 2026
Cooper Companies Q3 earnings beat estimates at $1.15, revenues miss at $1.07B on US destocking

The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.